Clinical Trial Update: Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Fazirsiran (TAK-999, ARO-AAT) in alpha-1 antitrypsin deficiency assessed safety, tolerability and pharmacodynamic effects. Results from…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Fazirsiran (fazirsiran)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2024-12-30